Use of Selective Serotonin Reuptake Inhibitors Is Associated with a Lower Risk of Colorectal Cancer among People with Family History

Zhang, Naiqi; Sundquist, Jan; Sundquist, Kristina; Ji, Jianguang

doi:10.3390/cancers14235905

Cited by 5 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 152 Population‐based cohort studies also revealed that there is a correlation between the utilisation of SSRIs and a potentially lower chances of developing CRC in people with a family history of this disease. 153 A recent evaluation and meta‐analysis of published observational studies unveiled that taking SSRIs was associated with decreased likelihood of developing HCC, with a dose‐dependent tendency. 154 SSRIs have also shown an association with a decreased risk of HCC and may lower the chances of HCC in patients with HBV in a dosage‐dependent fashion.…”

Section: Therapeutic Potential Of Serotonergic Pathway In Cancermentioning

confidence: 99%

“…An epidemiological study reported that the administration of SSRIs in patients with persistent clinical depression significantly decreased their likelihood of developing CRC 152 . Population‐based cohort studies also revealed that there is a correlation between the utilisation of SSRIs and a potentially lower chances of developing CRC in people with a family history of this disease 153 . A recent evaluation and meta‐analysis of published observational studies unveiled that taking SSRIs was associated with decreased likelihood of developing HCC, with a dose‐dependent tendency 154 .…”

Section: Therapeutic Potential Of Serotonergic Pathway In Cancermentioning

confidence: 99%

See 1 more Smart Citation

Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities

Chen,

Huang,

et al. 2024

Clinical & Translational Med

View full text Add to dashboard Cite

BackgroundSerotonin (5‐hydroxytryptamine) is a multifunctional bioamine serving as a neurotransmitter, peripheral hormone and mitogen in the vertebrate system. It has pleiotropic activities in central nervous system and gastrointestinal function via an orchestrated action of serotonergic elements, particularly serotonin receptor‐mediated signalling cascades. The mitogenic properties of serotonin have garnered recognition for years and have been exploited for repurposing serotonergic‐targeted drugs in cancer therapy. However, emerging conflicting findings necessitate a more comprehensive elucidation of serotonin's role in cancer pathogenesis.Main body and conclusionHere, we provide an overview of the biosynthesis, metabolism and action modes of serotonin. We summarise our current knowledge regarding the effects of the peripheral serotonergic system on tumourigenesis, with a specific emphasis on its immunomodulatory activities in human cancers. We also discuss the dual roles of serotonin in tumour pathogenesis and elucidate the potential of serotonergic drugs, some of which display favourable safety profiles and impressive efficacy in clinical trials, as a promising avenue in cancer treatment.Key points Primary synthesis and metabolic routes of peripheral 5‐hydroxytryptamine in the gastrointestinal tract. Advanced research has established a strong association between the serotonergic components and carcinogenic mechanisms. The interplay between serotonergic signalling and the immune system within the tumour microenvironment orchestrates antitumour immune responses. Serotonergic‐targeted drugs offer valuable clinical options for cancer therapy.

show abstract

Section: Therapeutic Potential Of Serotonergic Pathway In Cancermentioning

confidence: 99%

Section: Therapeutic Potential Of Serotonergic Pathway In Cancermentioning

confidence: 99%

Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities

Chen,

Huang,

et al. 2024

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…44 There is evidence that selective serotonin reuptake inhibitors (SSRI) reduce proliferation, leading to the death of tumor cells. 45…”

Section: Antipsychotic Agentsmentioning

confidence: 99%

Recent advances in anticancer drug discovery: A review

Tadesse,

Nemomsa,

Beyene

2023

IJPCA

View full text Add to dashboard Cite

Cancer is a process of uncontrolled cell proliferation that leads to the development of an abnormally growing tumor, determining initially a local disease that might spread, impairing other organs or important processes. One of the most fatal diseases in recent times, cancer kills many lives each year. The effective management of this condition has been impacted by the variances in the disease across the globe, the impact of the medical facilities that are available, and other socioeconomic issues. The aim of this study was to summaries previously published articles regarding recent advances in anticancer drug discoveries. In this review, previously published literature regarding recent advances in anticancer drug discovery collected from journals through PubMed Central, Google Scholar, and Science Direct from March 20 to May 12 was identified well, and points that I assumed were important and recent (2017–2023) were included.Based on my searches, numerous discoveries are identified and grouped as anticancer drug targets, plant derived advances, chemical compounds with in vivo or in vitro cytotoxic drug discovery, and repurposing advances. Based on a variety of articles published by scholars, this review summarizes some recent advancements in anticancer drug discovery. Under this broad topic, promising and clinically evidenced drug targets for anticancer drug binding, some drugs repurposed for cancer treatment, plant-derived advances in cancer therapy, and finally advances in novel chemical compounds in the area of cancer therapy are reviewed.

show abstract

“…They are generally considered to have fewer side effects and be less dangerous than older-generation antidepressants, such as tricyclic antidepressants, because they specifically target the serotonin transporter, rather than affecting a wide range of neurotransmitters (Wang et al, 2018). It was previously shown that drugs from the SSRI family exhibit anticancer properties (Nordenberg et al, 1999;Serafeim et al, 2003;Argov et al, 2009;Kast et al, 2013;Zhang et al, 2022). Moreover, it was suggested that SSRI members can be repositioned for cancer treatment (Peer and Margalit, 2006;Drinberg et al, 2014;Baú-Carneiro et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Cytotoxicity and reversal effect of sertraline, fluoxetine, and citalopram on MRP1- and MRP7-mediated MDR

Bin Kanner,

Teng,

Ganoth

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer is one of the leading causes of death worldwide, and the development of resistance to chemotherapy drugs is a major challenge in treating malignancies. In recent years, researchers have focused on understanding the mechanisms of multidrug resistance (MDR) in cancer cells and have identified the overexpression of ATP-binding cassette (ABC) transporters, including ABCC1/MRP1 and ABCC10/MRP7, as a key factor in the development of MDR. In this study, we aimed to investigate whether three drugs (sertraline, fluoxetine, and citalopram) from the selective serotonin reuptake inhibitor (SSRI) family, commonly used as antidepressants, could be repurposed as inhibitors of MRP1 and MRP7 transporters and reverse MDR in cancer cells. Using a combination of in silico predictions and in vitro validations, we analyzed the interaction of MRP1 and MRP7 with the drugs and evaluated their ability to hinder cell resistance. We used computational tools to identify and analyze the binding site of these three molecules and determine their binding energy. Subsequently, we conducted experimental assays to assess cell viability when treated with various standard chemotherapies, both with and without the presence of SSRI inhibitors. Our results show that all three SSRI drugs exhibited inhibitory/reversal effects in the presence of chemotherapies on both MRP1-overexpressed cells and MRP7-overexpressed cells, suggesting that these medications have the potential to be repurposed to target MDR in cancer cells. These findings may open the door to using FDA-approved medications in combination therapy protocols to treat highly resistant malignancies and improve the efficacy of chemotherapy treatment. Our research highlights the importance of investigating and repurposing existing drugs to overcome MDR in cancer treatment.

show abstract

Use of Selective Serotonin Reuptake Inhibitors Is Associated with a Lower Risk of Colorectal Cancer among People with Family History

Cited by 5 publications

References 46 publications

Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities

Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities

Recent advances in anticancer drug discovery: A review

Cytotoxicity and reversal effect of sertraline, fluoxetine, and citalopram on MRP1- and MRP7-mediated MDR

Contact Info

Product

Resources

About